The CMA cleared the deal in five weeks. The same regulator spent a year investigating the complete-nutrition business Danone already owns.
Britain’s competition watchdog cleared Danone’s roughly €1 billion purchase of Huel on 20 August, ending a review it opened on 15 July. Danone already makes nutritionally complete food. Aptamil and Cow & Gate hold about 71% of the UK infant formula market, and Nutricia’s Fortisip and Nutrison feed hospital patients across Europe. Those products sit inside legal categories that fix their composition and restrict how Danone can advertise them. Huel sits outside all of it. At £864 million on £254 million of revenue and roughly £25 million of EBITDA, Danone paid about 34 times earnings for a business whose main asset is the right to sell complete nutrition to healthy adults without asking a doctor.
Walk into a Boots in Tring, ten minutes from Huel’s head office, and you can buy two Danone products that promise the same thing. One is Fortisip, a small bottle of nutritionally complete liquid for patients who cannot eat enough. A dietitian decides who gets it, the NHS pays for most of it, and European regulation says it must be used under medical supervision. The other, once this deal closes, is a Huel Ready-to-Drink shake bought by a software developer who skipped lunch. Same promise, same shelf-stable format, same French owner. One of them required a prescription pad and a year of clinical evidence. The other required an Instagram budget.
That gap is what Danone bought.
What Happened
The Competition and Markets Authority confirmed on Thursday that it had cleared Danone Holdings (UK)’s anticipated acquisition of Huel Limited without referring the deal to a Phase 2 investigation. The CMA said that on the information currently available, it would not take the case further. Danone said the transaction remains subject to final completion conditions.
Danone signed the definitive agreement on 23 March 2026, describing Huel as an extension into what it calls the Complete Nutrition space. Neither party disclosed the price. The Financial Times put it at about €1 billion, the Wall Street Journal reported $1.2 billion, and UK outlets settled on £864 million. Sellers include Morgan Stanley Investment Management’s 1GT climate private equity strategy, which invested in 2023, and Highland Europe.
The regulatory calendar is where the story gets interesting. The CMA opened its file on 27 May and ran an invitation to comment through 10 June. It launched the formal Phase 1 inquiry on 15 July, with a statutory deadline of 11 September. Clearance arrived on 20 August, roughly three weeks early.
Count the days. From signing to clearance: 150. From the start of the statutory investigation to clearance: 36. Three quarters of the elapsed regulatory time happened before the legal clock started, in the untimed pre-notification phase where the parties assemble the CMA’s evidence pack.
Nobody made Danone do any of it. UK merger control under the Enterprise Act 2002 is voluntary and non-suspensory. No law required Danone to notify, and no law barred it from closing. Companies file because the CMA can investigate a completed merger for four months afterwards and order the buyer to unwind it. Danone spent five months buying certainty it could have skipped.
Huel gave the CMA plenty to look at. Danone’s UK portfolio runs from Aptamil and Cow & Gate through Activia and Actimel to Evian and Volvic, and Alpro already sells a meal-replacement drink in British supermarkets. The overlap question was real. The full-text decision has not been published yet, so the market definition the CMA used remains private.
The Backstory
Huel is eleven years old. Julian Hearn and James Collier, a former NHS dietitian, started it in 2014 selling powdered meals to people who found lunch tedious. James McMaster joined as chief executive in 2017. The company employs around 350 people, manufactures its dry blends at a Milton Keynes site, and has moved from a purely direct-to-consumer operation into 17,000 UK stores with more than 100,000 stocking points.
The filed accounts show a business that found its footing late. Revenue for the year to 31 July 2024 reached £214 million, up 16%, with pre-tax profit of £13.8 million and adjusted EBITDA of £18.2 million. The year before that, adjusted EBITDA was under £10 million and profit for the year was £2.2 million. FY2025 revenue came in at £254 million, with UK sales up 26.5% to £139.3 million, and the company indicated an EBITDA margin around 10%.
Danone, meanwhile, has been buying complete nutrition on the other side of the regulatory wall. It took a majority stake in Kate Farms, a US maker of plant-based clinical nutrition used in more than 1,400 hospitals, completing in July 2025. Kate Farms sits inside Danone North America Medical Nutrition alongside Nutricia, Real Food Blends and Functional Formularies. In June 2026 Danone agreed to buy MADE Group in Asia Pacific. Three health-nutrition acquisitions in fourteen months, two of them plant-based complete nutrition.
The CMA knows the older half of that portfolio well. It launched a market study into infant formula on 20 February 2024 and published a 185-page final report on 14 February 2025. The findings: three firms supply more than 90% of the UK market, prices rose between 18% and 36% over two years depending on brand, and parents show almost no price sensitivity. Danone alone holds roughly 71% through Aptamil and Cow & Gate.
The CMA’s diagnosis matters more than the share figure. Every infant formula sold in Britain meets the same legally mandated composition, so the products are close to interchangeable. Manufacturers cannot advertise first-stage formula and cannot promote price cuts. Competition therefore relocated to branding, and to advertising follow-on formula and toddler milks, where the restrictions do not apply. The CMA recommended extending the advertising ban to follow-on formula. The UK government responded in December 2025 saying further work was required.
Danone’s most dominant British category is the one where it has the least freedom to sell.
The Plan
Antoine de Saint-Affrique calls the strategy Renew Danone, and Huel slots into functional nutrition rather than the Specialized Nutrition division that houses Nutricia. Danone’s press release praised Huel’s digital execution, its direct-to-consumer sales and its fan base across the UK, Europe and the United States.
McMaster framed the trade from his side: Danone brings infrastructure, distribution and R&D capability, and the target is new markets and more people. Read that against Huel’s own numbers and the logic is clear enough. UK retail grew 26.5% last year. Danone can put Huel into grocery accounts on three continents that a 350-person company in Hertfordshire would spend a decade negotiating.
Danone also arrives with a laboratory. Huel has spent years defending its formulations against the ultra-processed food critique, and Danone employs the clinical nutrition scientists who built Fortisip and Neocate. Applying that evidence base to a consumer brand is a plausible way to make complete nutrition respectable rather than faintly dystopian.
The group needs the growth. Danone reported FY2025 sales of €27,283 million, up 4.5% like-for-like, with recurring operating margin of 13.4%. H1 2026 sales reached €13,936 million, up 3.5%, with margin at 13.3%. Free cash flow fell 27.3% to €852 million and net debt rose to €9.0 billion. Guidance for the year sits at 3% to 5% like-for-like growth. Huel grew 19%.
The Business Model Angle
Danone now owns two versions of the same product, and their economics have almost nothing in common.
Version one is Specialized Nutrition: infant formula, medical nutrition, Fortisip, Nutrison, Neocate, Kate Farms. It grew 7.4% like-for-like in 2025 at a recurring operating margin of 21.7%, up 112 basis points, against a group margin of 13.4%. That is Danone’s best business by a distance. Regulation built the margin. Composition rules, clinical evidence requirements and hospital procurement relationships keep new entrants out, and the CMA’s own study documents how weakly buyers respond to price.
Regulation also built the ceiling. Danone cannot advertise infant formula. It cannot discount it. Demand for medical nutrition is set by clinicians and payer budgets, not by how good the marketing is. A category that legally forbids you from telling healthy people about your product cannot grow faster than the population of sick people and newborns.
Version two is Huel. No mandated composition, no medical supervision, no prescription, no reimbursement, no advertising ban. Huel sells its powders and shakes as ordinary food. The trade-off is that the same freedom belongs to everyone else, which is why the margin sits near 10% instead of 21.7%. Nothing stops a rival from launching next Tuesday, so Huel has to keep paying for attention it can never own.
Danone paid 34 times EBITDA for version two while its own shares trade around 11 to 12 times. Put another way, £864 million at Danone’s own 11.1x multiple requires about £78 million of EBITDA. Huel produces roughly £25 million. Its earnings need to triple.
Hold the margin at 10% and that implies revenue near £780 million. Huel grew 18.7% last year. Sustaining that rate gets the company there in about six and a half years, and it has to hold that rate against a much larger base.
That is the deal in one line. Danone swapped balance sheet capacity for permission. It owns a protected, high-margin nutrition business that cannot grow much, and it has bought an unprotected, low-margin one that might grow without limit, at a price that only works if the second thing happens.
The pattern generalizes past food. In any regulated category, the licence that protects your margin is the same licence that caps your addressable market. Pharmaceutical companies discovered this with cash-pay direct channels. The GLP-1 reformulation wave in packaged food is the same trade in miniature, with manufacturers reaching for an unregulated badge because the regulated claims are too slow and too expensive to earn. Escaping regulation and escaping pricing power tend to be the same move.
The Risk
Several things could break this.
The freedom Danone paid for belongs to everybody. “Complete nutrition” carries no legal definition in the UK. Any private-label supplier can print it on a bag of oat powder and pea protein tomorrow, and Aldi and Lidl have already demonstrated in infant formula that they will enter a category once the economics look attractive. Danone bought a category position in a category with no walls.
The marketing lever has limits, and Huel has already hit them. In August 2024 the Advertising Standards Authority banned two Huel Facebook ads featuring Steven Bartlett after seven complaints, ruling that omitting his directorship at the company breached CAP Code rules on misleading advertising. The regulator that constrains Huel is not the CMA. It is the ASA and general food-claims law, and both tighten as a brand gets larger and more visible.
The growth is coming from the wrong place for margin. UK retail sales rose 26.5% last year, and third-party e-commerce trackers put growth on huel.com in the mid-single digits over the same period. Shelf space costs listing fees, trade spend and a retailer’s cut. Huel’s 10% EBITDA margin was built partly on selling direct. Growing through Tesco and GNC pushes it down before Danone’s scale pushes it back up. HelloFresh’s subscription economics show how expensive owning the customer relationship becomes once acquisition costs stop falling, and what happens when a direct brand hands its operations to somebody else is a live cautionary tale in the same aisle.
Now the argument against all of the above. Specialized Nutrition earns 21.7% precisely because regulation keeps competitors out, which is an argument for buying more regulated assets, not fewer. Danone’s answer would be that it bought Kate Farms too, so it is running both plays at once. The pricing is defensible on comps as well: P&G paid roughly six times forward revenue for Thorne this month, and Danone paid 3.4 times for Huel. Either Danone got the better deal, or bidders marked Huel down for a direct channel that is growing more slowly than its retail one. The Thorne transaction sets the going rate for DTC health brands, and Huel cleared at a discount to it.
The distribution synergy is also real rather than rhetorical. Danone sells into pharmacies, hospitals, convenience, grocery and out-of-home across 120 markets. Huel sells into 17,000 UK stores and a website. Tripling EBITDA over six years sounds ambitious for Huel alone and unremarkable for a brand plugged into that network, which is presumably how the deal got approved internally. Nestlé faces the same growth arithmetic and has been building Vital Pursuit organically rather than buying a category leader.
The weakest part of the bull case is timing. Danone is paying a growth multiple for a business whose fastest-growing channel is its least profitable one, at a moment when weight-loss drugs are reshaping demand for portion-controlled high-protein food in ways nobody has modelled with confidence.
Quick Questions
Did Danone have to notify the CMA at all? No. UK merger control is voluntary and non-suspensory. Danone chose to file because the CMA can unwind a completed merger within four months, and a five-month delay costs less than that risk.
Why did the CMA look at a French dairy group buying a British powder brand? Danone sells in overlapping British categories, including a meal-replacement drink under Alpro. Since January 2025 the CMA can also assert jurisdiction where the acquirer holds a 33% share of supply in any UK sector and UK turnover above £350 million, with no overlap required. Danone’s roughly 71% of infant formula clears that comfortably.
What is Huel worth on the numbers? £254 million of FY2025 revenue and roughly £25 million of EBITDA at the company-indicated 10% margin. At £864 million that is 3.4 times revenue and about 34 times earnings.
Is complete nutrition a regulated category? Infant formula and food for special medical purposes are. Both carry mandated composition, and infant formula carries advertising restrictions. Huel’s products sit outside both, which is the entire commercial point.
What happens to Huel’s brand under Danone? Watch the marketing budget rather than the formulation. Huel’s value was built by advertising to healthy people, and Danone’s institutional muscle memory comes from categories where advertising is illegal.
The Business Model Analyst Take
Danone did not buy a formula. It has had the formula since Nutricia started making it, and its scientists arguably make a better one.
It bought a customer who is allowed to buy without permission.
That distinction is the whole £864 million, and it is worth carrying into any category where a regulator stands between the product and the buyer. Regulation is a two-sided contract. It hands you a 21.7% operating margin, a moat made of clinical evidence and procurement contracts, and a competitor list short enough to fit on an index card. In exchange it takes your advertising, your pricing freedom and your ability to sell to anyone who is not sick.
Most incumbents in regulated categories read the first half of that contract and stop. They spend decades optimising inside the walls, defending share, and treating the ceiling as physics. Then a company with no clinical department and a good Instagram account builds a £254 million business selling a worse version of the same product to people the incumbent was never allowed to talk to, and the incumbent has to buy it at 34 times earnings.
Huel’s founders did not out-science Danone. They picked an aisle where the rules let them speak.
The number to watch now is not revenue growth. It is Huel’s EBITDA margin two years after the retail expansion. If Danone’s distribution lifts it toward the group’s 13.4% while volume compounds, the price looks smart in hindsight. If shelf space and trade spend grind it below 10% while private label copies the claim for free, Danone will have paid a growth multiple for a commodity with a logo on it.
